|
Jun 25
|
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
|
|
Jun 17
|
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
|
|
Apr 18
|
Should We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?
|
|
Feb 24
|
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
|